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Preoperative chemoradiotherapy (CRT) is a standard treatment for locally advanced rectal
cancer patients. Despite the benefits of CRT, its use in non-responder patients can be asso-
ciated with increased toxicities and surgical resection delay. The identification of CRT
response biomarkers, such as microRNAs, could improve the management of these
patients. We have studied the microRNA expression in pretreatment endoscopy biopsies
from rectal cancer patients treated with CRT to identify potential microRNAs able to predict
CRT response and clinical outcome of these patients.
Material andmethods
RNA from pretreatment endoscopy biopsies from 96 rectal cancer patients treated with pre-
operative CRT were studied. Pathological response was graded according to the tumor
regression grade (TRG) Dworak classification. In the screening phase, 377 miRNAs were
studied in 12 patients with extreme responses (TRG0-1 vs TRG4). The potential role as pre-
dictive biomarkers for CRT response, disease-free survival (DFS) and overall survival (OS)
of the miRNAs identified in the screening phase were validated in the whole cohort.
Results
In the screening phase, an 8-miRNAs CRT-response signature was identified: let-7b, let-7e,
miR-21, miR-99b, miR-183, miR-328, miR-375 and miR-483-5p. In the validation phase,
miR-21, miR-99b and miR-375 emerged as CRT response-related miRNAs while miR-328
and let-7e emerged as prognostic markers for DFS and OS. Interestingly, ROC curve analy-
sis showed that the combination of miR-21, miR-99b and miR-375 had the best capacity to
distinguish patients with maximum response (TRG4) from others.
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Conclusions
miR-21, miR-99b and miR-375 could add valuable information for individualizing treatment
in locally advanced rectal cancer patients.
Introduction
Rectal cancer accounts for approximately one-third of all colorectal tumors, which is one of
the leading causes of cancer death in the world[1]. Preoperative chemoradiotherapy (CRT) has
been incorporated into common clinical practice for the treatment of locally advanced rectal
cancers (T3-T4 or N +). The most frequently used chemotherapy agent is 5-Fluorouracil in
combination with concurrent fractionation radiotherapy. Preoperative CRT has multiple
advantages, including the higher radiosensitivity of tissues before surgery, the lower rate of
toxicities and the higher probability of achieving sphincter preservation due to tumor down-
staging[2]. Of note, the rate of pathological response after treatment has been associated with
prognosis[2]. Pathological complete response (pCR; ypT0N0), which occurs in 15–25% of the
patients, has been linked with lower rates of local recurrences. However, preoperative CRT has
not been associated with better disease-free survival (DFS) or overall survival (OS) rates[3, 4].
In clinical practice, there are no validated biomarkers to correctly identify those patients that
will not respond, so patient selection remains exclusively a clinically based decision.
MicroRNAs (miRNAs) are short non-coding RNAs that regulate post-transcriptional gene
expression by binding primarily to the 30 untranslated region (UTR) of their target mRNA and
repressing its translation[5]. miRNAs are aberrantly expressed and deregulated in cancer[6]
where depending on their targets can act either as oncogenes or tumor suppressor genes[7].
Different profiles of miRNAs differentially expressed between rectal cancer and normal rectal
tissue have been described[8]. These miRNAs target multiple genes involved in crucial path-
ways in tumor biology. Moreover, some miRNAs conforming the rectal cancer miRNAome
are differentially expressed in colon cancer[9]. Several studies have shown the involvement of
miRNAs in resistance to chemotherapy or CRT, both in vitro and in vivo studies[10–14]. Iden-
tifying patients who will not respond to treatment is crucial to avoid unnecessary treatment,
potential toxicities and a delay of surgery. In this setting, miRNAs could serve as predictive
biomarkers to select the most optimal treatment in each case in order to individualize therapy.
Previous studies with a limited number of patients have proposed some miRNAs as predictors
of response to preoperative CRT in rectal cancer[15–20].
In the present work, primarily we analyzed the miRNA profile in extreme responder vs
non-responder patients to preoperative CRT for rectal cancer treated in our institution. miR-
NAs differentially expressed between responders and non-responders were studied in a larger
series of patients of the same institution and correlated with treatment response and survival.
Material andmethods
Study population
Ninety-six patients with a diagnosis of rectal adenocarcinoma in a clinical stage II or III
(uT3-T4 and/or uN+) and consecutively treated in Hospital Universitari Mutua Terrassa were
selected. All patients had received neoadjuvant chemotherapy with 5-Fluouracil 225 mg/m2/
day x 7 days in continuous infusion and in combination with pelvic locoregional radiotherapy
(45–50 Gy). Six to 8 weeks after completion, all patients underwent surgery. All surgical
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specimens were evaluated and classificated according to TNM 7th edition and pathological
response was graded according to the tumor regression grade (TRG) Dworak classification
[21]. Approval for the study was obtained from the Institutional Review Board of the Hospital
Universitari Mutua Terrassa, Barcelona, Spain.
RNA extraction
Total RNA was extracted from formalin-fixed paraffin-embedded tumor tissues from pretreat-
ment endoscopy biopsies using RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Ther-
moFisher Scientific, Waltham, MA, USA) as per the manufacturer’s protocol. The
concentration of RNA was determined using the NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies, Wilmington, DE).
miRNA quantification
In the screening phase, 377 miRNAs were analyzed in 12 selected patients to identify miRNAs
associated with response to neoadjuvant treatment. miRNA profiling was performed with Taq-
Man Array Human MicroRNA A Cards v2.0 (Applied Biosystems, ThermoFisher Scientifics)
using pre-amplification as previously described[22]. Expression levels were calculated by the
2-ΔΔCtmethod. Real-time quantitative PCR reactions were performed on an ABI 7900 HT
Sequence Detection System (Applied Biosystems). Normalization was performed with
RNU48, based on preliminary analyses comparing the stability of RNU48, RNU44 and
MammU6; RNU48 had the lowest variability of expression in the miRNA expression patient
data set and was therefore used in this study. All miRNAs that were expressed in less than 10%
of samples or with an unreliable quantification were excluded from further analysis, leaving a
set of 184 miRNAs.
In the validation phase, selected miRNAs identified in the screening phase were validated
in the whole cohort of 96 patients by single Real Time TaqMan MicroRNA Assays in an
Applied Biosystems 7500 Sequence Detection System as previously described[23].
Statistical methods
Data on miRNA expression were analyzed using TIGRMultiexperiment viewer version 4.0
software (The Institute for Genomic Research, and ArrayAssist software, Stratagene, http://
www.tm4.org/mev), R software version 3.4 (The R Foundation for Statistical Computing c/o
Institute for Statistics and Mathematics, Wirtschaftsuniversität Wien, http://www.r-project.
org/) and SPSS v.15.0 (Chicago, IL, USA). Hierarchical clustering was performed using
Pearson squared correlation and average linkage. To identify miRNAs with significant differ-
ential expression between response groups, two multivariate permutation tests were per-
formed: significance analysis of microarrays (SAM) and Student’s t-test based on multivariate
permutation (with random variance model). Differences between miRNAs were considered
statistically significant if the P-value was<0.001 (t-test) or false discovery rate<0.1% (SAM).
ROC curves were calculated using R package pROC[24]. The multivariate analysis for treat-
ment response was performed by using Binary Logistic regression.
The prognostic impact on DFS and OS, of the identified miRNAs was also evaluated. DFS
and OS were defined as the time between surgery and either recurrence or death (DFS) or
death from any cause (OS). Optimal cutoffs of miRNA expression data for DFS and OS were
assessed by means of maximally selected log-rank statistics[25] using the Maxstat package (R
statistical package, v. 2.8.1, Vienna, Austria). DFS and OS were calculated with the Kaplan–
Meier method and compared using the log-rank test. All prognostic variables in the univariate
analysis with a P-value at or below 0.1 were included in the multivariate analysis performed
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Table 1 shows the main characteristics of the 96 patients included in the study. Sixty-six
patients were male and 30 female. Their median age was 66 years (range 38–84 years). Four-
teen (15%) patients had clinical stage II and 82 (85%) patients had clinical stage III. 58% of
patients received adjuvant therapy after resection. 63% of patients had a downstaging of the
disease after treatment, 25% had a pathological complete response (ypT0N0M0) and 27% had
a TRG 4.
Screening phase: Identification of miRNAs related to tumor response
For the primary analyses of miRNA differentially expressed in extreme responders, we selected
6 patients with complete regression (TRG4: no tumor cells detectable in the resected primary
tumor after chemoradiotherapy) and 6 patients without response or minor response (TRG
0–1).
Supervised analysis by SAM and t-test of 12 patients revealed 8 common miRNAs differen-
tially expressed in the TRG4 samples compared to the TRG0-1 samples: let-7b, let-7e, miR-21,
miR-99b, miR-183, miR-328, miR-375 and miR-483-5p (Fig 1A)
Table 1. Main clinical characteristics of the patients included in the study.
Characteristic N = 96 DFS OS
Sex Male 66 (69) 0.619 0.614
Female 30 (31)
Median Age (range) 66 (38–84)
<60 29 (30) 0.154 0.564
>60 67 (70)
Clinical stage pre CRT II 14(15) 0.531 0.748
III 82 (85)
Adjuvant therapy No 40 (42) 0.237 0.346
Yes 5-FU 7 (7)
FOLFOX 42 (44)
Other 7 (7)
ypT ypT0 26 (27) 0.010 0.033
ypT1-2 23 (24)
ypT3-4 47 (49)
ypN pN0 66 (69) 0.013 0.003
pN+ 30 (31)




Downstaging No 35 (37) 0.002 0.001
Yes 61 (63)
Tumor regression grade (TRG) 0–3 70 (72.9) 0.116 0.149
4 26 (27.1)
https://doi.org/10.1371/journal.pone.0206542.t001
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Validation phase I: Analysis of tumor response-related miRNAs in the
whole cohort
The eight miRNAs were studied in the whole cohort (S1 Table and S1 Data) to validate their
potential value to predict response to neoadjuvant treatment. Interestingly, those patients who
developed complete response (TRG4) had significantly lower miR-21 (p = 0.0127, Fig 1B),
miR-99b (p = 0.0049, Fig 1C) and miR-375 expression levels (p = 0.0039, Fig 1D). Moreover,
let-7b expression was progressively reduced from TRG0 to TRG4 (Pearson r2 = -0.241,
p = 0.014; ANOVA p = 0.0356, Fig 1E). No significant differences were observed for the other
miRNAs.
Receiver operating characteristic (ROC) curves were generated to investigate the potential
utility of miR-21, miR-99b and miR-375 as predictive biomarkers of response to neoadjuvant
treatment. The area under the curve (AUC) value for miR-21, miR-99b and miR-375 was
0.6691 (95% confidence interval (CI) = 0.55–0.79; p = 0.012), 0.671 (95% CI = 0.55–0.79;
p = 0.01) and 0.691 (95% CI = 0.57–0.81; p = 0.0042) respectively (Fig 2). In the optimum trun-
cation point the sensitivity and specificity was 58.3% and 76.3% for miR-21 (<0.09), 60% and
62% for miR-99b (<0.15) and 60% and 76.6% for miR-375 (<0.07).
Interestingly, the combination of the 3 miRNAs (sum of their expression) improved the dis-
crimination with an AUC value of 0.736 (95% confidence interval (95% CI = 0.62–0.85;
p = 0.00043) with 60% sensitivity and 82.9% specificity to distinguish patients with maximum
response (TRG4) from others (Fig 2A). In order to compare the impact of the miRNA
Fig 1. Identification of miRNAs related to treatment response. A)Hierarchical cluster analysis showing the 8 miRNAs identified
differentially expressed in TRG4 vs TRG0-1 samples in the screening phase. B)miR-21,C)miR-99b,D)miR-375 and E) let-7e expression
levels in the whole cohort according treatment response (TRG). The black bars in the scatter plots indicate mean ± SEM, and in blue we have
highlighted the values from the 12 samples included in the screening phase. TRG 0–3 group is composed of 70 patients, one TRG0, 14 TRG1,
14 TRG2 and 41 TRG3, while the TRG4 group is composed of 26 patients.
https://doi.org/10.1371/journal.pone.0206542.g001
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combination with other clinical factors, pre-CRT clinical stage and pre-CRT CEA levels were
included in the analysis. The miRNA combination was a more reliable predictive biomarker
than the clinical factors (Fig 2B).
Finally, we performed a multivariate analysis of response to neoadjuvant treatment includ-
ing sex, age, stage pre-CRT, CEA levels pre-CRT and the miRNA combination. Only the
miRNA combination emerged as an independent marker of neoadjuvant treatment response
(odds ratio [OR]: 0.439; 95% CI: 0.242–0.797; p = 0.007).
Validation phase II: Prognosis impact of the tumor response-related
miRNAs
Overall median DFS and median OS were not reached. Overall, mean DFS was 79.8 months
(95% CI: 71.5–88.1), and mean OS was 89.7 months (95% CI: 82.9–96.5).
There were no statistical significant differences in DFS or OS regarding sex, age, clinical
stage, or administration of adjuvant chemotherapy treatment or the TRG (Table 1). On the
other hand, there were significant differences on DFS and OS related to pathological stage
(DFS: p = 0.047; OS: p = 0.044) or downstaging with CRT treatment (DFS: p = 0.002; OS:
p = 0.001).
Expression levels of the eight identified miRNAs were correlated with DFS and significant
associations were observed for let-7e and miR-328. Mean DFS for patients with low let-7e lev-
els was 68.11 months (95% CI: 55.9–80.3), while it was 83.8 months (95% CI: 75.7–91.9) for
those with high levels (P = 0.003, Fig 3A). Mean DFS for patients with high miR-328 levels
Fig 2. (A) ROC curve analyses to evaluate the potential utility of miR-21, miR-99b, miR-375 and their combination to
distinguish patients with maximum response to neoadjuvant treatment (TRG4) from others. (B) ROC curve analysis
comparing the miRNA combination with pre-CRT clinical stage and CEA levels.
https://doi.org/10.1371/journal.pone.0206542.g002
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was 33.2 months (95% CI: 22.2–44.1), while it was 82.9 months (95% CI: 74.4–91.3) for those
with low levels (P = 0.041, Fig 3C). A trend to significance was also observed for miR-375
where mean DFS for patients with high levels was 71.7 months (95% CI: 61.3–82), while it was
90.8 months (95% CI: 79.5–102.3) for those with low levels (P = 0.080, Fig 3D). Moreover, we
also tested the prognostic impact of the miRNA combination (miR-21, miR-99b and miR-375)
and we observed a trend for DFS, where mean DFS for patients with low levels was 74.5
months (95% CI: 64.03–84.9), while it was 78.8 months (95% CI: 68.5–89.1) for those with
high levels (P = 0.068; Fig 4)
Only let-7e was significantly associated with OS. Mean OS for patients with low let-7e levels
was 83.1 months (95% CI: 72.9–93.3), while it was 87.7 months (95% CI: 81.2–94.2) for those
with high levels (P = 0.028, Fig 3B).
In the multivariate analyses for DFS (including all factors with univariate p-value�0.1:
ypN, ypT, pathological stage, downstaging, miR-328 and let-7e), ypT0(OR, 0.278; p = 0.021),
high miR-328 expression (OR, 4.340; p = 0.004) and low let-7e (OR, 6.196; p = 0.001)
emerged as independent prognostic markers for DFS, while downstaging (OR, 0.182; P<
0.003), high miR-328 (OR, 3.905; P = 0.047) and low let-7e expression (OR, 3.678; P = 0.044)
were independent markers for OS (Table 2).
Discussion
Preoperative CRT is a standard treatment for patients with locally advanced rectal cancer and
its use is widespread in general clinical practice. However, about 20–40% of the patients do not
Fig 3. Kaplan–Meier curves for (A) DFS according to let-7e expression, (B) OS according to let-7e expression, (C)
DFS according to miR-328 expression, and (D) DFS according to miR-375 expression.
https://doi.org/10.1371/journal.pone.0206542.g003
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respond to this neoadjuvant treatment[2]. Patients with a locally advanced rectal cancer are
commonly explored with a rectal endoscopy, providing sufficient tissue for diagnosis and for
molecular analyses before the start of the treatment. Despite sample availability for molecular
analysis, currently there are no clinically validated biomarkers to correctly identify those
patients that will not respond. Recent studies have shown an association between pretreatment
serum carcinoembryonic antigen (CEA) levels with pCR and survival[26, 27]. Despite this,
patient selection is still based on clinical stage and many patients are treated with potential
toxic treatments and the definitive surgical resection is delayed [28].
Fig 4. Kaplan-Meier curve for DFS according to the miRNA combination (sum of expression of miR-21, miR-99b
andmiR-375).
https://doi.org/10.1371/journal.pone.0206542.g004
Table 2. Multivariate analysis for DFS and OS.
Disease-Free Survival Odds Ratio (95% CI) P-value
ypN0 1.668 (0.458–6.069) 0.438
ypT0 0.278 (0.094–0.826) 0.021
Pathological stage I 0.655 (0.062–6.951) 0.725
Downstaging 0.556 (0.209–1.480) 0.240
High miR-328 4.340 (1.595–11.811) 0.004
Low let-7e 6.196 (2.166–17.722) 0.001
Overall Survival Odds Ratio (95% CI) P-value
ypN0 1.104 (0.233–5.236) 0.900
ypT0 0.606 (0.090–4.072) 0.607
Pathological stage I 0.611 (0.025–14.877) 0.762
Downstaging 0.182 (0.058–0.571) 0.003
High miR-328 3.905 (1.017–14.998) 0.047
Low let-7e 3.678 (1.038–13.038) 0.044
https://doi.org/10.1371/journal.pone.0206542.t002
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In our present work, we primarily found an eight-miRNA signature that characterize
extreme responders (TRG4) using a screening group of patients with well characterized
responses (6 TRG0-1 patients vs 6 TRG4 patients). The validation of the eight-miRNA signa-
ture in the whole cohort of 96 patients confirmed miR-21, miR-99b, miR-375 and let-7b as
preoperative CRT response-related miRNAs. miR-21, miR-99b and miR-375 where signifi-
cantly downregulated in TRG4 patients vs TRG0-3, while let-7b levels slowly decrease as TRG
group increase, with its lower levels in the TRG4 group of patients. Since we were interested in
identifying extreme responder patients, we focused in miR-21, miR-99b and miR-375. The
ROC curve analysis indicated that these 3 miRNAs were able to predict preoperative CRT
response. Interestingly, the combination of them, expressed as the sum of their values, had the
best AUC value with a 60% sensitivity and 82.9% specificity to distinguish patients with maxi-
mum response from others.
In line with our results, miR-21 overexpression was correlated with non-complete response
in a study with 76 rectal adenocarcinomas biopsies before preoperative CRT(RT+5-FU)[29].
However, other studies reported the contrary, that miR-21 overexpression correlated with
complete tumor regression[30] [31]. In Eriksen et al. study[31], the one with a great cohort,
miR-21 was downregulated in responder patients in the test cohort (n = 55, p = 0.062) while
was upregulated in responders in the validation cohort (n = 130, p = 0.035). This indicates that
the role of miR-21 in preoperative CRT response need to be further studied. In line with our
results, in vitro studies showed that miR-21 have been found to be overexpressed in 5-FU-
resistant colorectal cancer cell lines[32].
miR-99b have been reported upregulated after 5-FU treatment and have predicted targets
involved in regulation of autophagy in HT-29 cells[33]. Autophagy has been increasingly rec-
ognized as a prosurvival cellular response activated in times of stress during chemotherapy[34]
and can promote chemotherapy resistance. miR-99b targets include mTOR signaling pathway
which inhibition has been previously related in breast cancer cells with an increase in autop-
hagy[35].
miR-375 overexpression have been previously related to resistance to ionizing radiation
and etoposide treatment in gastric cancer cell lines through p53 regulation[36] and elevated
miR-375 has been linked to recurrent gastric cancer[37]. In addition, in cervical cancer cell
lines overexpression of miR-375 have been related to paclitaxel resistance[38]. In colon cancer,
miR-375 have been related to cetuximab resistance through regulation of the AKT pathway by
targeting the tumor suppressor gene PHLPP1[39]. Recently, Conde-Muiño et al. described
that miR-375 trough regulation of cMyc played a role in chemoresistance to neoadjuvant treat-
ment in locally advanced rectal cancer[40]. All these results are in line with our observation
that non-responder patients present high levels of miR-375.
Previous works with lower number of patients have described other miRNAs correlated
with response to CRT treatment in rectal cancer that we have not identified in our study: over-
expression of miR-31 have been correlated with poor response and worse OS[41]; miR-622
and miR-630 had a 100% sensitivity and specificity in selecting patients with maximum
response in a study with 38 patients treated with Capecitabine and Oxaliplatin and radiother-
apy[15].
In addition, we studied the potential role of the 8 miRNAs found in the screening phase
with the clinical outcome of the patients. In this setting, we found significant differences on
DFS regarding expression of let-7e and miR-328 and significant differences on OS depending
of expression of let-7e. Moreover, patients with low levels of miR-375 (that correlated with bet-
ter response) had a trend to better DFS. Interestingly, let-7e and miR-328 emerged as indepen-
dent prognostic factors for DFS and OS in the multivariate analyses. Patients with high levels
of miR-328 and those patients with low levels of let-7e had shorter DFS and OS.
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High expression levels of let-7e have been previously correlated with better response to
CRT[18]. This result is in line with the results obtained in our screening phase, where we
observed that responder patients (TRG4) had higher let-7e levels. Despite we could not vali-
date this result in the whole cohort for treatment response; let-7e emerged as an independent
biomarker for DFS and OS. The members of let-7 family have been previously associated with
patient outcome in multiple tumors including colorectal cancer[42].
In summary, in the present work we have identified a miRNA signature involved in preop-
erative CRT response and outcome of rectal cancer patients. Although the present study
included a relatively large series with a homogeneous population and treatment; the presented
results have to be taken with caution since it is a retrospective study and need to be confirmed
in a prospective study. However, miRNAs identified in the present study could be a valuable
additional tool for individualizing treatment in locally advanced rectal cancer patients.
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